CARBOPLATINE ACCORD 10 mg/ml
Sponsors
Seagen Inc., F. Hoffmann-La Roche AG, Institut Bergonie, Incyte Corp., Oncopole Claudius Regaud
Conditions
First-line treatment of PD-L1-positive recurrent or metastatic head and neck squamous cell carcinomasLocalized digestive Neuroendocrine CarcinomasPatients with locally advanced or metastasic Non-Small Cell Lung Carcinoma.Previously Untreated Advanced or Metastatic Non-Squamous Non−Small Cell Lung CancerResectable Stage I-III Non-Small Cell Lung Cancer (NSCLC)Squamous Carcinoma of the Anal CanalUntreated Advanced or Metastatic Non-Small Cell Lung CancerUrothelial cancer
Phase 1
Phase 2
OPTIMUNE-LUNG : INTEGRATIVE ANALYSIS OF THE TUMOR MICROENVIRONMENT AND OPTIMIZATION OF THE IMMUNOTHERAPY DURATION IN NON-SMALL CELL LUNG CANCER PATIENTS
Active, not recruitingCTIS2023-509490-23-00
Start: 2021-08-03Target: 80Updated: 2025-05-13
Reduction in the number of chemotherapy cycles in combination with Pembrolizumab in first-line treatment of PD-L1-positive recurrent or metastatic head and neck squamous cell carcinomas
RecruitingCTIS2024-514875-16-00
Start: 2024-10-21Target: 86Updated: 2025-10-30
Phase II study to evaluate the efficacy of 12-month neoadjuvant chemotherapy in terms of disease-free survival in patients with localized digestive neuroendocrine carcinomas - NEONEC D19-01
WithdrawnCTIS2024-515603-19-00
Target: 78Updated: 2024-08-13
Phase II study to evaluate the efficacy of 12-month neoadjuvant chemotherapy in terms of disease-free survival in patients with localized digestive neuroendocrine carcinomas - NEONEC D19-01
Not yet recruitingCTIS2024-515603-19-01
Target: 78Updated: 2025-10-14
Phase 3
C5701003 - An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer
Active, not recruitingCTIS2023-503421-19-00
Start: 2020-08-26Target: 703Updated: 2025-08-19
INCMGA 0012-303: A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2)
CompletedCTIS2024-512331-72-00
Start: 2020-12-22End: 2025-09-26Target: 201Updated: 2025-07-16
A Phase I-III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients with Resectable Stage I-III Non-Small Cell Lung Cancer, selected according to Biomarker Status
RecruitingCTIS2024-511239-91-00
Start: 2025-05-05Target: 54Updated: 2025-11-10
A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB AND PEMBROLIZUMAB VERSUS PEMBROLIZUMAB AND PEMETREXED AND CARBOPLATIN OR CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED, KRAS G12C-MUTATED, ADVANCED OR METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
RecruitingCTIS2024-518365-10-00
Start: 2025-10-28Target: 282Updated: 2026-01-13